Investigation of Potential Drug-Drug Interactions Due to Linezolid Use in Anesthesia Intensive Care Unit: A Retrospective Study

Abstract

Objective This study aims to clarify the possible interactions of Linezolid, a drug used during infection treatment in intensive care units, with other drugs and to provide information to stakeholders in clinical use. Material and Method Data from the files of intensive care patients over the age of 18 who received at least 24 hours of inpatient treatment between 2017-2023 in the intensive care unit of the Department of Anesthesiology and Re- animation in Suleyman Demirel University and who used at least one other drug in addition to the active substance Linezolid during this period were used. All these data were evaluated with the Lexi-Interact pro- gram. Results 68(36%) patients included in the study were exposed to polypharmacy for 2-22 days, 69(36.5%) patients for 23-45 days, and 52(27.5%) patients for 46-197 days during their treatment. A total of 655 interactions were identified. Of these, 17(8.99%) type A, 172(91%) type B, 183(96.83%) type C, 184(97.35%) type D, and 99(52.38%) type X interactions were detected. As a result of the examination of potential drug-drug inter- actions (pDDIs) in terms of dual drug use with Linezol- id, it was seen that the most frequent type C interac- tion could occur with Quetiapine (33;17.20%), type D interaction with Salbutamol (94;49.70%), and type X interactions which are not recommended for use side by side with Linezolid could occur with Metoclopropa- mide (44;23.30%) and Escitalopram (11;5.80%). Conclusion Linezolid-treated ICU patients exhibited a high preva- lence of potential drug–drug interactions, particularly involving sympathomimetic and serotonergic agents. These findings highlight the importance of routine interaction screening and careful monitoring when linezolid is prescribed in critically ill patients.

Keywords

• Drug-Drug Interaction
• Linezolid
• Inten- sive Care Unit
• Infection
• Polypharmacy

Supporting Institution

This study was supported by the Scientific Research Projects Coordination Unit of Suleyman Demirel University with project code TYL-2024-9236

Project Number

TYL-2024-9236

Ethical Statement

Our study was conducted retrospectively after receiving approval from the ethics committee of Suleyman Demirel University Faculty of Medicine (dated 16/08/2023-no.13/184) by examining the files of patients over the age of 18 who were treated as inpatients for at least 24 hours between 2017 and 2023 in the iıntensive care unit of the Department of Anesthesiology and Reanimation of Suleyman Demirel Faculty of Medicine and who used at least one different medication in addition to the active substance called Linezolid during this period.

References

1. 1. Rodrigues MCS, De Oliveira C. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review. Rev Lat Am Enfermagem. 2016;24. doi:10.1590/1518-8345.1316.2800 PubMed PMID: 27598380.
2. 2. Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a re- view of its properties, function, and use in critical care. Drug Des Devel Ther. 2018 Jun 18;12:1759–67. doi:10.2147/DDDT. S164515 PubMed PMID: 29950810.
3. 3. Douros A, Grabowski K, Stahlmann R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Ex- pert Opin Drug Metab Toxicol. 2015 Dec 2;11(12):1849–59. do i:10.1517/17425255.2015.1098617 PubMed PMID: 26457865.
4. 4. Gatti M, Raschi E, De Ponti F. Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-phar- macokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol. 2021 Feb 1;77(2):233–9. doi:10.1007/S00228-020-02990-1 PubMed PMID: 32901348.
5. 5. Drug Information App | UpToDate Lexidrug | Wolters Kluwer [In- ternet]. [cited 2024 Dec 9]. Available from: https://www.wolter- skluwer.com/en/solutions/uptodate/about/mobile-apps/lexidrug
6. 6. Asci H, Sonmez Y, Saygin M, et al. Investigation of the pre- sence of potential drug-drug interactions in the adult intensive care unit: a retrospective study. Medical Journal of Süleyman Demirel University. 2016;23(3):87–96.
7. 7. Cattaneo D, Gervasoni C, Corona A. The Issue of Pharmaco- kinetic-Driven Drug-Drug Interactions of Antibiotics: A Narrative Review. Antibiotics (Basel). 2022 Oct 1;11(10). doi:10.3390/ ANTIBIOTICS11101410 PubMed PMID: 36290068.
8. 8. Bisaso KR, Mukonzo JK, Ette EI. A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro. In Silico Pharmacol. 2023 Oct 27;11(1). doi:10.1007/S40203-023-00168-Y PubMed PMID: 37899968.

9. 9. Santos TRA, Silveira EA, Pereira LV, et al. Potential drug-drug interactions in older adults: A population-based study. Geri- atr Gerontol Int. 2017 Dec 1;17(12):2336–46. doi:10.1111/ GGI.13070 PubMed PMID: 28635169.
10. 10. Holford NHG. Clinical pharmacokinetics and pharmacodynami- cs of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet. 1986;11(6):483–504. doi:10.2165/00003088- 198611060-00005 PubMed PMID: 3542339.
11. 11. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006 Dec 28;355(26):2725–32. doi:10.1056/ NEJMOA061115 PubMed PMID: 17192537.
12. 12. Buetti N, Timsit JF. Management and Prevention of Central Ve- nous Catheter-Related Infections in the ICU. Semin Respir Crit Care Med. 2019;40(4):508–23. doi:10.1055/S-0039-1693705 PubMed PMID: 31585477.
13. 13. Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquili- ne-Pretomanid-Linezolid Regimens for Drug-Resistant Tuber- culosis. N Engl J Med. 2022 Sep;387(9):810–23. doi:10.1056/ NEJMOA2119430 PubMed PMID: 36053506.
14. 14. Kaya Kılıç E, Bulut C, Sönmezer MÇ, et al. Risk factors for linezo- lid-associated thrombocytopenia and negative effect of carbape- nem combination. J Infect Dev Ctries. 2019 Oct 31;13(10):886– 91. doi:10.3855/JIDC.10859 PubMed PMID: 32084018.
15. 15. Kuscu F, Ulu A, Inal AS, et al. Potential Drug-Drug Interactions with Antimicrobials in Hospitalized Patients: A Multicenter Po- int-Prevalence Study. Med Sci Monit. 2018 Jun 20;24:4240–7. doi:10.12659/MSM.908589 PubMed PMID: 29924770.
16. 16. Gun UZ, Bahcecioglu OF, Gok S. Linezolid drug interactions: A retrospective study. Medicine Science International Medical Journal. 2020;9(2):320–2.
17. 17. Pehlivanlı A, Özgün Ç, Erad ÇF, et al. Incompatibility, Y-Site In- compatibility and Incompatibility Management for Intravenously Administered Drugs in Intensive Care Unit. Anestezi Dergisi. 2022;30(2):151–62. doi:10.54875/JARSS.2022.49002
18. 18. Gülçebı İdrız Oğlu M, Küçükibrahimoğlu E, Karaalp A, et al. Po- tential drug-drug interactions in a medical intensive care unit of a university hospital. Turk J Med Sci. 2016 Jan 1;46(3):812–9. doi:10.3906/sag-1504-147 PubMed PMID: 27513261.
19. 19. Zhang J, Ma D, Chen M, et al. Prevalence and clinical sig- nificance of potential drug-drug interactions among lung transplant patients. Front Pharmacol. 2024;15. doi:10.3389/ FPHAR.2024.1308260 PubMed PMID: 38379901.
20. 20. Sola CL, Bostwick JM, Hart DA, et al. Anticipating potenti- al linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise. Mayo Clin Proc. 2006;81(3):330–4. doi:10.4065/81.3.330 PubMed PMID: 16529136.
21. 21. Ramsey TD, Lau TTY, Ensom MHH. Serotonergic and adre- nergic drug interactions associated with linezolid: a critical re- view and practical management approach. Ann Pharmacother. 2013;47(4):543–60. doi:10.1345/APH.1R604 PubMed PMID: 23548646.
22. 22. Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharma- cokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dext- romethorphan HBr. J Clin Pharmacol. 2001 Jan 1;41(5):563–72. doi:10.1177/00912700122010302 PubMed PMID: 11361053.
23. 23. Davis JJ, Buck NS, Swenson JD, et al. Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil. J Clin Anesth. 2013 Feb;25(1):52–4. doi:10.1016/J.JCLINANE.2012.05.002 Pub- Med PMID: 23391344.
24. 24. Hassamal S, Miotto K, Dale W, et al. Tramadol: Understan- ding the Risk of Serotonin Syndrome and Seizures. Am J Med. 2018 Nov 1;131(11):1382.e1-1382.e6. doi:10.1016/J.AMJ- MED.2018.04.025 PubMed PMID: 29752906.
25. 25. Baldo BA. Toxicities of opioid analgesics: respiratory depres- sion, histamine release, hemodynamic changes, hypersensitiv- ity, serotonin toxicity. Arch Toxicol. 2021 Aug 1;95(8):2627–42. doi:10.1007/S00204-021-03068-2 PubMed PMID: 33974096.
26. 26. El-Okdi NS, Lumbrezer D, Karanovic D, et al. Serotonin syn- drome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. Am J Ther. 2014;21(4). doi:10.1097/MJT.0B013E3182456D88 PubMed PMID: 24158007.
27. 27. Hunter B, Kleinert MM, Osatnik J, et al. Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil? Anesth Analg. 2006;102(5):1589. doi:10.1213/01. ANE.0000215200.84401.BF PubMed PMID: 16632855